• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 451533 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414743194 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414743194 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Bristol-Myers Squibb Rise to a New 52-Week High

Published on Fri, 03/01/2013 - 15:10
By Peter Chu

Bristol-Myers Squibb (NYSE:BMY) traded today at a new 52-week high of $37.25. So far today approximately 5.9 million shares have been exchanged, as compared to an average 30-day volume of 9.5 million shares.

In the past 52 weeks, Bristol-Myers Squibb share prices have been bracketed by a low of $30.64 and a high of $37.25 and are now at $37.08, 21% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.9%.

Bristol-Myers Squibb (NYSE:BMY) is currently priced 3.2% above its average consensus analyst price target of $35.91. The stock should find initial support at its 50-day moving average (MA) of $34.99 and further support at its 200-day MA of $33.86.

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Take-Two Interactive Software Looks to C...

Shares of Take-Two Interactive Software (NASDAQ:TTWO) traded at a new 52-week high toda ...

Shares of Talisman Energy Fall Below Pre...

Shares of Talisman Energy (NYSE:TLM) traded at a new 52-week low today of $6.12. Appro ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hanover Insurance (NYSE:THG) traded at a new 52-week high today of $66.88. T ...

Recent 52-Week Low Surpassed in Shares o...

Shares of Taseko Mines (AMEX:TGB) traded at a new 52-week low today of $1.35. This new ...

Transglobe Energy Looks to Continue to T...

Shares of Transglobe Energy (NASDAQ:TGA) traded today at $4.35, breaking its 52-week lo ...

Shares of TFS Financial Rise Above Previ...

Shares of TFS Financial (NASDAQ:TFSL) traded today at $15.09, breaking its 52-week high ...

Watch for Continued Gains in Shares of T...

Teva Pharmaceutical Industries (NASDAQ:TEVA) traded at a new 52-week high today of $55. ...

Shares of Integrys Energy Rise to a New ...

Integrys Energy (NYSE:TEG) traded at a new 52-week high today of $72.23. So far today ...